Lorlatinib is an ALK and ROS1 targeted next-generation tyrosine kinase inhibitor (TKI). Real-world treatment related adverse event (TRAE) data are limited. We reviewed TRAEs and therapeutic efficacy for advanced non-small-cell lung cancer (NSCLC) patients receiving lorlatinib at our centre.

Exon 19 deletions, exon 21 L858R and exon 20 insertions represent the most frequent alterations in EGFR mutated non-small cell lung cancer (NSCLC). These alterations now all have approved targeted therapies. In contrast, there is limited data assessing activity of EGFR-directed therapy for uncommon EGFR alterations. We sought to describe clinical outcomes of patients with rare EGFR mutations that received systemic anticancer therapy (SACT) at our institution.